SPEECH-PROCESSING
Speech Processing Solutions , the worldwide leader in professional dictation has received excellent reviews for its Philips SpeechMike Premium. The proven and almost indestructible dictation microphone offers users superior audio quality, coupled with unique antimicrobial housing and excellent ergonomics. The fully customizable dictation microphone saves time, increases efficiency and ultimately lowers costs for professionals across a variety of industry sectors.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151118005582/en/
The leader in healthcare
Philips SpeechMike has become a household name in many industries, particularly in the healthcare sector where the dictation microphone seamlessly integrates into leading healthcare IT systems. “It’s been a very reliable system for us. We’ve had great long-term success (…) I would highly recommend the SpeechMike Premium to any hospital with demanding dictation needs” explains Dave Baumgardner, Director of Information Management, Union Hospital in Dover, Ohio, USA.
Philips SpeechMike: A history of innovation
Speech Processing Solutions celebrated their 60th anniversary last year, driven by setting standards in the dictation industry by successful innovations. The original Philips SpeechMike was first launched in 1996. “The current top model, Philips SpeechMike Premium, is the result of almost two decades of attention to detail and striving for excellence through listening to customer’s needs from all over the world” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions.
Made for speech recognition
Thanks to its special features such as the free floating microphone, the polished surface for non-sensitivity to touch noise, or the unique audio-optimized microphone grill, the Philips SpeechMike creates studio-like audio recordings . Together they successfully reduce unwanted surround sounds which enables two radiologists for example, to dictate simultaneously in one room without any interference. The clear recording levels enable the highest possible speech recognition accuracy. The dictation device is designed to work in perfect harmony with speech recognition software and has been awarded the highest possible Nuance speech recognition rating. This underlines Philips' position as global leader in audio competence, also underpinned by superior customer reviews.
Unlike many competitor products, the Philips SpeechMike offers exceptional features such as its antimicrobial housing, which is especially important in medical settings. The device fits perfectly into the hand where the ergonomic keyboard layout guarantees comfortable operation, even when dictating for several hours. Philips also carries out most extensive ‘stress tests’, making sure all devices are of exceptional quality, setting the benchmark in the dictation microphone industry. Dr. Thomas Brauner makes the point: “As our customers say: The best or nothing!”
For more information on the Philips SpeechMike please visit: www.philips.com/dictation
About Speech Processing Solutions
Speech Processing Solutions is the global number one in professional dictation. Founded in Austria in 1954 as part of Philips, the company has been the driving force in speech-to-text innovations for over 60 years. Always striving for excellence and putting emphasis on outstanding quality, the company has designed groundbreaking products, such as the portable Philips Pocket Memo voice recorder , the Philips SpeechMike Premium dictation microphone and the Philips SpeechExec dictation recorder app for smartphones. The latest innovation, Philips SpeechLive , makes dictation quicker and more convenient than ever before, by bringing secure dictation workflow to the cloud and enabling seamless speech-to-text with the new service Philips SpeechScribe. With solutions perfectly tailored to individual industry needs, Speech Processing Solutions has helped millions of satisfied customers around the globe save time and resources, allowing them to work as efficiently as possible.
Connect with Speech Processing Solutions on:
Facebook: http://www.facebook.com/philipsvoicetracer
Twitter @speech_com: http://www.twitter.com/speech_com
YouTube: http://www.youtube.com/philipsdictation
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
View source version on businesswire.com: http://www.businesswire.com/news/home/20151118005582/en/
./ContentItem/FormatPhilips SpeechMike Premium - the best or nothing
Contact:
Speech Processing Solutions
Richard Bancej
Richard.bancej@speech.com
Tel:
+43 1 60101-4191
www.philips.com/dictation
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom